Author: Jennifer Levy

C3 is Expanding the Field of LGMD2A/R1 Researchers

Coalition to Cure Calpain 3 (C3) is attracting more researchers to study – and ultimately cure – limb-girdle muscular dystrophy 2A (LGMD2A/R1). We have worked tirelessly to bring more scientists, research, and dollars to focus on and unravel our understudied

FDA Patient Listening Session on LGMDs held October 20, 2020

On October 20th, 2020, the LGMD community was able to meet with the FDA to share our patient experiences. This was a patient-led listening session organized by a consortium of advocacy organizations, including Coalition to Cure Calpain 3. The session

C3 is Increasing Scientific Collaboration to Fight LGMD2A/R1

Coalition to Cure Calpain 3 (C3) initiates scientific collaboration to bring the best minds together to fight limb-girdle muscular dystrophy type 2A (LGMD2A/R1). Working to cure LGMD2A/R1 requires connecting ideas, scientists, clinicians, patient groups and companies to elevate research to

C3 is Connecting Patients to Clinical Studies

Coalition to Cure Calpain 3 is a vital hub connecting patients with limb-girdle muscular dystrophy type 2A (LGMD2A/R1) to clinical studies. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness, we

Building the First LGMD2A/R1 Patient Registry

Coalition to Cure Calpain 3 (C3) has launched the first and only limb-girdle muscular dystrophy type 2A (LGMD2A/R1) patient registry. In celebration of ten years of progress in our mission to fund research for a cure and raise global awareness,

Promising study identifies compound that improves muscle in LGMD2A/R1 mice

A new publication from Dr. Melissa Spencer’s laboratory at the University of California Los Angeles identifies a compound that mimics the effects of exercise in a mouse model of limb girdle muscular dystrophy type 2A (LGMD2A/R1). These studies may point

Coalition to Cure Calpain 3

Author: Jennifer Levy

C3 is Expanding the Field of LGMD2A/R1 Researchers

FDA Patient Listening Session on LGMDs held October 20, 2020

C3 is Increasing Scientific Collaboration to Fight LGMD2A/R1

C3 is Connecting Patients to Clinical Studies

Building the First LGMD2A/R1 Patient Registry

Promising study identifies compound that improves muscle in LGMD2A/R1 mice

C3 is connecting patients with one another!

C3 is Building Scientific Leadership

C3 is Putting LGMD on the Map!

C3 Celebrates a Decade of Achievement